全文获取类型
收费全文 | 245553篇 |
免费 | 49764篇 |
国内免费 | 3904篇 |
专业分类
耳鼻咽喉 | 2754篇 |
儿科学 | 7426篇 |
妇产科学 | 2352篇 |
基础医学 | 31311篇 |
口腔科学 | 9531篇 |
临床医学 | 29435篇 |
内科学 | 44705篇 |
皮肤病学 | 6497篇 |
神经病学 | 24612篇 |
特种医学 | 9999篇 |
外国民族医学 | 39篇 |
外科学 | 27218篇 |
综合类 | 20408篇 |
现状与发展 | 23篇 |
一般理论 | 11篇 |
预防医学 | 14426篇 |
眼科学 | 3453篇 |
药学 | 20403篇 |
83篇 | |
中国医学 | 15108篇 |
肿瘤学 | 29427篇 |
出版年
2024年 | 358篇 |
2023年 | 2446篇 |
2022年 | 4465篇 |
2021年 | 7440篇 |
2020年 | 11395篇 |
2019年 | 16168篇 |
2018年 | 15408篇 |
2017年 | 17061篇 |
2016年 | 16402篇 |
2015年 | 16052篇 |
2014年 | 20218篇 |
2013年 | 22745篇 |
2012年 | 17906篇 |
2011年 | 18337篇 |
2010年 | 15646篇 |
2009年 | 11604篇 |
2008年 | 12001篇 |
2007年 | 10903篇 |
2006年 | 9993篇 |
2005年 | 9163篇 |
2004年 | 8014篇 |
2003年 | 7375篇 |
2002年 | 6393篇 |
2001年 | 5233篇 |
2000年 | 3665篇 |
1999年 | 2104篇 |
1998年 | 1489篇 |
1997年 | 1302篇 |
1996年 | 1114篇 |
1995年 | 971篇 |
1994年 | 761篇 |
1993年 | 593篇 |
1992年 | 540篇 |
1991年 | 486篇 |
1990年 | 404篇 |
1989年 | 354篇 |
1988年 | 351篇 |
1987年 | 298篇 |
1986年 | 242篇 |
1985年 | 304篇 |
1984年 | 270篇 |
1983年 | 202篇 |
1982年 | 199篇 |
1981年 | 193篇 |
1980年 | 155篇 |
1979年 | 146篇 |
1978年 | 82篇 |
1977年 | 51篇 |
1976年 | 61篇 |
1975年 | 44篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
《Archives of Cardiovascular Diseases》2022,115(10):505-513
Central illustration: cumulative major adverse cardiac events (MACE) and bioresorbable vascular scaffold (BVS) thrombosis rates after 1, 2, 3, 4 and 5 years. 相似文献
2.
Rosario Gulias-Cañizo Anell Lagunes-Guillén Arturo González-Robles Erika Sánchez-Guzmán Federico Castro-Muñozledo 《Burns : journal of the International Society for Burn Injuries》2019,45(2):398-412
Background
Since recent reports have shown that (-)-Epigallocatechin-3-gallate (EGCG) could be used for treating proliferative and inflammatory disorders, we explored its use for the management of corneal chemical burns.Materials and methods
Initially, EGCG was assayed on the rabbit corneal epithelial cell line RCE1(5T5) to establish the best testing conditions, and to avoid unwanted outcomes in the experimental animals. Then, we studied its effects on cell proliferation, cell cycle progression and cell differentiation. Afterwards, we instilled EGCG in experimental grade II corneal alkali burns in mice, three times a day up to 21 days, and evaluated by slit lamp examination and histological sections of corneal epithelial, corneal endothelial and stromal edema, as well as the presence of inflammatory cells and neovascularization.Results
EGCG reduced cell growth and led to a decline in the proportion of proliferative cells in a concentration dependent manner. At 10 μM, EGCG promoted cell differentiation, an effect not related with apoptosis or cytotoxicity. When 10 μM EGCG was instilled in corneal alkali burns in mice three times a day up to 21 days, EGCG significantly reduced corneal opacity and neovascularization. The improved clinical appearance of the cornea was associated to a controlled epithelial growth; epithelial morphology was similar to that observed in normal epithelium and contrasted with the hyperproliferative, desquamating epithelium observed in control burn wounds. EGCG reduced corneal, stromal and endothelial edema, and wound inflammation.Conclusion
This work constitutes the first evidence for the use of EGCG in the acute phase of a corneal alkali burn, representing a possible novel alternative to improve patient outcomes as an add-on therapy. 相似文献3.
4.
5.
6.
7.
8.
9.
Katherine M. Duszynski Nicole L. Pratt John W. Lynch Jesia G. Berry Michael S. Gold 《Vaccine》2019,37(2):280-288
Objective
To determine whether differences in combination DTaP vaccine types at 2, 4 and 6?months of age were associated with mortality (all-cause or non-specific), within 30?days of vaccination.Design
Observational nationwide cohort study.Setting
Linked population data from the Australian Childhood Immunisation Register and National Death Index.Participants
Australian infants administered a combination trivalent, quadrivalent or hexavalent DTaP vaccine (DTaP types) between January 1999 and December 2010 at 2, 4 and 6?months as part of the primary vaccination series. The study population included 2.9, 2.6, & 2.3?million children in the 2, 4 and 6?month vaccine cohorts, respectively.Main outcome measures
Infants were evaluated for the primary outcome of all-cause mortality within 30?days. A secondary outcome was non-specific mortality (unknown cause of death) within 30?days of vaccination. Non-specific mortality was defined as underlying or other cause of death codes, R95 ‘Sudden infant death syndrome’, R96 ‘Other sudden death, cause unknown’, R98 ‘Unattended death’, R99 ‘Other ill-defined and unspecified cause of mortality’ or where no cause of death was recorded.Results
The rate of 30?day all-cause mortality was low and declined from 127.4 to 59.3 deaths per 100,000 person-years between 2 and 6?month cohorts. When compared with trivalent DTaP vaccines, no elevated risk in all-cause or non-specific mortality was seen with any quadrivalent or hexavalent DTaP vaccines, for any cohort.Conclusion
Use of routine DTaP combination vaccines with differing disease antigens administered during the first six months of life is not associated with infant mortality. 相似文献10.
雄激素不敏感综合征(androgen insensitivity syndrome,AIS)又称为睾丸女性化综合征(testicular feminization syndrome,TFS),是一种X连锁遗传病,是男性假两性畸形中较常见的类型,可分为完全型AIS和不完全型AIS,其原因主要是雄激素受体(androgen receptor,AR)基因的突变导致其对雄激素产生抵抗和不应答。本文回顾南京医科大学附属妇产医院2例CAIS患者的临床资料及诊疗过程,以期能进一步提高对该病的认知及诊治水平。 相似文献